VERU · Veru Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt regarding our ability to continue as a going concern for a period of twelve months subsequent to the issuance date of the financial statements included in this report. Certain elements of our operating plan to alleviate the conditions that raise substantial doubt, including but not limited to our ability to secure equity financing or other financing alternatives, are outside of our control and cannot be included in management's evaluation under the requirements of ASC 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months subsequent to the issuance date of the financial statements included in this report.”View the 10-Q filed Aug 10, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-13 | BARNETTE K GARY |
Chief Scientific Officer |
Buy↑
|
Common Stock
|
1,800 |
| 2026-05-04 | Hyun Grace |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029. |
Common Stock Option
|
97,000 |
| 2026-05-04 | FISCH HARRY |
Director, Chief Corporate Officer |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029. |
Common Stock Option
|
160,000 |
| 2026-05-04 | STEINER MITCHELL SHUSTER |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029. |
Common Stock Option
|
604,000 |
| 2026-05-04 | Lu Lucy |
Director, President, CEO |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029. |
Common Stock Option
|
104,000 |
| 2026-05-04 | Katzovitz Loren Mark |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029. |
Common Stock Option
|
102,000 |
| 2026-05-04 | BARNETTE K GARY |
Chief Scientific Officer |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029. |
Common Stock Option
|
160,000 |
| 2026-05-04 | Greco Michele |
Chief Admin Officer and CFO |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029. |
Common Stock Option
|
164,000 |
| 2026-05-04 | Rankowitz Michael L |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029. |
Common Stock Option
|
100,000 |
| 2025-12-05 | Greco Michele |
Chief Admin Officer and CFO |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of December 5, 2026, December 5, 2027 and December 5, 2028. |
Common Stock Option
|
27,000 |
| 2025-12-05 | BARNETTE K GARY |
Chief Scientific Officer |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of December 5, 2026, December 5, 2027 and December 5, 2028. |
Common Stock Option
|
27,000 |
| 2025-12-05 | FISCH HARRY |
Director, Chief Corporate Officer |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of December 5, 2026, December 5, 2027 and December 5, 2028. |
Common Stock Option
|
27,000 |
| 2025-12-05 | Lu Lucy |
Director, President, CEO |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of December 5, 2026, December 5, 2027 and December 5, 2028. |
Common Stock Option
|
4,000 |
| 2025-12-05 | STEINER MITCHELL SHUSTER |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of December 5, 2026, December 5, 2027 and December 5, 2028. |
Common Stock Option
|
100,000 |
| 2025-12-05 | Rankowitz Michael L |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of December 5, 2026, December 5, 2027 and December 5, 2028. |
Common Stock Option
|
3,000 |
| 2025-12-05 | Hyun Grace |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of December 5, 2026, December 5, 2027 and December 5, 2028. |
Common Stock Option
|
6,000 |
| 2025-12-05 | Katzovitz Loren Mark |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of December 5, 2026, December 5, 2027 and December 5, 2028. |
Common Stock Option
|
6,000 |
| 2025-10-01 | Hyun Grace |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of October 1, 2026, October 1, 2027 and October 1, 2028. |
Common Stock Option
|
3,000 |
| 2025-10-01 | Lu Lucy |
Director, President, CEO |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of October 1, 2026, October 1, 2027 and October 1, 2028. |
Common Stock Option
|
6,000 |
| 2025-10-01 | Rankowitz Michael L |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of October 1, 2026, October 1, 2027 and October 1, 2028. |
Common Stock Option
|
7,000 |
| 2025-05-06 | Rankowitz Michael L |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 6, 2026, May 6, 2027 and May 6, 2028. |
Common Stock Option
|
15,000 |
| 2025-05-06 | BARNETTE K GARY |
Chief Scientific Officer |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 6, 2026, May 6, 2027 and May 6, 2028. |
Common Stock Option
|
104,000 |
| 2025-05-06 | Katzovitz Loren Mark |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 6, 2026, May 6, 2027 and May 6, 2028. |
Common Stock Option
|
90,000 |
| 2025-05-06 | Greco Michele |
Chief Admin Officer and CFO |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 6, 2026, May 6, 2027 and May 6, 2028. |
Common Stock Option
|
108,000 |
| 2025-05-06 | Hyun Grace |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 6, 2026, May 6, 2027 and May 6, 2028. |
Common Stock Option
|
55,000 |
| 2025-05-06 | Lu Lucy |
Director, President, CEO |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 6, 2026, May 6, 2027 and May 6, 2028. |
Common Stock Option
|
30,000 |
| 2025-05-06 | STEINER MITCHELL SHUSTER |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 6, 2026, May 6, 2027 and May 6, 2028. |
Common Stock Option
|
378,000 |
| 2025-05-06 | FISCH HARRY |
Director, Chief Corporate Officer |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of May 6, 2026, May 6, 2027 and May 6, 2028. |
Common Stock Option
|
104,000 |
| 2025-03-13 | Hyun Grace |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Option grant associated with new appointment to Chair of the Nominating and Corporate Governance Committee. Options for one-third of the shares vest on each of March 13, 2026, March 13, 2027 and March 13, 2028. |
Common Stock Option
|
5,000 |
| 2025-03-13 | Katzovitz Loren Mark |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Option grant associated with new appointment to Nominating and Corporate Governance committee. Options for one-third of the shares vest on each of March 13, 2026, March 13, 2027 and March 13, 2028. |
Common Stock Option
|
10,000 |
| 2025-02-19 | Rankowitz Michael L |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported above is the weighted average transaction price. The range of prices for such transactions is $0.55 to $0.59. Upon request by the Commission staff, the reporting person will provide full information regarding the number of shares sold at each separate price. |
Common Stock
|
54,721 |
| 2025-02-18 | Rankowitz Michael L |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported above is the weighted average transaction price. The range of prices for such transactions is $0.54 to $0.57. Upon request by the Commission staff, the reporting person will provide full information regarding the number of shares sold at each separate price. |
Common Stock
|
95,279 |
| 2024-10-01 | Lu Lucy |
Director, President, CEO |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of October 1, 2025, October 1, 2026 and October 1, 2027. |
Common Stock Option
|
70,000 |
| 2024-10-01 | Eisenberger Mario |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of October 1, 2025, October 1, 2026 and October 1, 2027 |
Common Stock Option
|
45,000 |
| 2024-10-01 | Hyun Grace |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of October 1, 2025, October 1, 2026 and October 1, 2027. |
Common Stock Option
|
40,000 |
| 2024-10-01 | Rankowitz Michael L |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of October 1, 2025, October 1, 2026 and October 1, 2027. |
Common Stock Option
|
85,000 |
| 2024-08-06 | Rankowitz Michael L |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of August 6, 2025, August 6, 2026 and August 6, 2027. |
Common Stock Option
|
10,000 |
| 2024-08-06 | Lu Lucy |
Director, President, CEO |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of August 6, 2025, August 6, 2026 and August 6, 2027. |
Common Stock Option
|
20,000 |
| 2024-08-06 | Hyun Grace |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of August 6, 2025, August 6, 2026 and August 6, 2027. |
Common Stock Option
|
40,000 |
| 2024-08-06 | Katzovitz Loren Mark |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of August 6, 2025, August 6, 2026 and August 6, 2027. |
Common Stock Option
|
80,000 |
| 2024-08-06 | Eisenberger Mario |
Director |
Award↑
Filing footnotes — Common Stock Option (Direct)
Options for one-third of the shares vest on each of August 6, 2025, August 6, 2026 and August 6, 2027. |
Common Stock Option
|
30,000 |
| 2024-05-24 | BARNETTE K GARY |
Chief Scientific Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported above is the weighted average transaction price. The range of prices for such transactions is $1.32 to $1.34. Upon request by the Commission staff, the reporting person will provide full information regarding the number of shares sold at each separate price. |
Common Stock
|
5,000 |
| 2024-05-24 | STEINER MITCHELL SHUSTER |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Dr. Steiner sold the shares referenced above to help address certain personal matters. The sold shares represent only 0.7% of Dr. Steiner's total beneficial ownership in the Company. After these sales, Dr. Steiner will beneficially own 9,615,996 shares, and will continue to be the Company's second largest shareholder. The price reported above is the weighted average transaction price. The range of prices for such transactions is $1.22 to $1.27. Upon request by the Commission staff, the reporting person will provide full information regarding the number of shares sold at each separate price. |
Common Stock
|
63,379 |
| 2024-05-24 | FISCH HARRY |
Director, Chief Corporate Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
Includes 541,144 shares held jointly by the reporting person and his spouse. |
Common Stock
|
4,000 |
| 2024-05-23 | STEINER MITCHELL SHUSTER |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Dr. Steiner sold the shares referenced above to help address certain personal matters. The sold shares represent only 0.7% of Dr. Steiner's total beneficial ownership in the Company. After these sales, Dr. Steiner will beneficially own 9,615,996 shares, and will continue to be the Company's second largest shareholder. |
Common Stock
|
300 |
| 2024-05-22 | STEINER MITCHELL SHUSTER |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Dr. Steiner sold the shares referenced above to help address certain personal matters. The sold shares represent only 0.7% of Dr. Steiner's total beneficial ownership in the Company. After these sales, Dr. Steiner will beneficially own 9,615,996 shares, and will continue to be the Company's second largest shareholder. The price reported above is the weighted average transaction price. The range of prices for such transactions is $1.38 to $1.40. Upon request by the Commission staff, the reporting person will provide full information regarding the number of shares sold at each separate price. |
Common Stock
|
6,504 |
| 2024-05-17 | STEINER MITCHELL SHUSTER |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Dr. Steiner sold the shares referenced above to help address certain personal matters. The sold shares represent only 1.7% of Dr. Steiner's total beneficial ownership in the Company. After these sales, Dr. Steiner will beneficially own 9,686,180 shares, and will continue to be the Company's second largest shareholder. The price reported above is the weighted average transaction price. The range of prices for such transactions is $1.3000 to $1.3450. Upon request by the Commission staff, the reporting person will provide full information regarding the number of shares sold at each separate price. |
Common Stock
|
28,066 |
| 2024-05-16 | STEINER MITCHELL SHUSTER |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Dr. Steiner sold the shares referenced above to help address certain personal matters. The sold shares represent only 1.7% of Dr. Steiner's total beneficial ownership in the Company. After these sales, Dr. Steiner will beneficially own 9,686,180 shares, and will continue to be the Company's second largest shareholder. The price reported above is the weighted average transaction price. The range of prices for such transactions is $1.3800 to $1.4650. Upon request by the Commission staff, the reporting person will provide full information regarding the number of shares sold at each separate price. |
Common Stock
|
59,788 |
| 2024-05-15 | STEINER MITCHELL SHUSTER |
Director, President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Dr. Steiner sold the shares referenced above to help address certain personal matters. The sold shares represent only 1.7% of Dr. Steiner's total beneficial ownership in the Company. After these sales, Dr. Steiner will beneficially own 9,686,180 shares, and will continue to be the Company's second largest shareholder. The price reported above is the weighted average transaction price. The range of prices for such transactions is $1.4800 to $1.5200. Upon request by the Commission staff, the reporting person will provide full information regarding the number of shares sold at each separate price. |
Common Stock
|
84,021 |
| 2024-05-15 | FISCH HARRY |
Director, Chief Corporate Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
Includes 541,144 shares held jointly by the reporting person and his spouse. |
Common Stock
|
6,711 |